Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) rose 6.59% to trade at $12.78 per share at last check-in premarket trading. During Tuesday’s session, Aldeyra stock fell -4.00%, closing at $11.99. The daily volume of ALDX stock was 1.74 million shares, which was less than the 50-day average of 2.7 million shares. In the run-up to tomorrow’s quarterly results, ALDX stock has been going up.
What is ALDX aiming at?
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Aldeyra Therapeutics is a clinical-stage biotechnology company specializing in finding new ways to treat patients with immune-mediated diseases. RASP (reactive aldehyde species) are elevated in ocular and systemic inflammatory disease, and they are targets of ADX-629 and reproxalap, two of the ALDX’s lead investigational compounds. ALDX’s clinical pipeline also includes ADX-2191, an inhibitor of dihydrofolate reductase in Phase 3 trials for proliferative vitreoretinopathy.
Read More
On May 6, 2021 at 8:00 a.m. ET, Aldeyra will host a conference call to report financial results and discuss recent business highlights, announced ALDX in a press release today.
Also in last week, ALDX announced that its 0.25% recproxalap ophthalmic solution, an investigational new drug, has been found to be safe and effective for patients with allergic conjunctivitis in the Phase 3 INVIGORATE Clinical Trial.
What ALDX is planning?
All secondary endpoints and the primary endpoint of the ALDX’s clinical trial were statistically significant. As part of its plans for the second half of 2021, Aldeyra (ALDX) will meet with the FDA to discuss the INVIGORATE results, along with the submission of a New Drug Application (NDA).
